PVRIG and non-small cell lung carcinoma: In conclusion at least one target molecule of the TIGIT/PVRIG pathway axis or the CD39/CD73 purinergic pathway was more frequently and at a higher MFI expressed in each tumor entity (BC: PVRIG, CD73; PC: TIGIT, CD39; NSCLC: CD73; MM: TIGIT, PVRIG, CD39).